ITCI
FY2026 EPS Estimate
$4.31
FY2026E EPS$4.31
FY2027E EPS$7.58

Analyst Sentiment

Wall St. Consensus
Buy
22 analysts·High coverage
66
Score
14 Buy (64%)8 Hold (36%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1464%
Hold
836%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$70.00
-46.9%
Consensus
$101.50
-23.0%
Bull
$132.00
+0.1%
12-Month Target Range22 analysts
$70.00$101.50$132.00
Current $131.87Consensus
Current Price
$131.87
Above Consensus
$30.37

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+38.49%
EPS+75.88%
FY2028
Rev+33.34%
EPS+51.00%
FY2029
Rev+33.20%
EPS+39.10%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029E
Revenue Avg$1.43B$1.98B$2.64B$3.52B
Low$1.13B$1.95B$2.09B$2.79B
High$1.68B$2.01B$3.11B$4.14B
EBITDA Avg$-1.01B$-1.39B$-1.86B$-2.47B
Low$-1.18B$-1.41B$-2.18B$-2.91B
High$-797M$-1.37B$-1.47B$-1.96B
EBIT Avg$-1.01B$-1.39B$-1.86B$-2.48B
Low$-1.18B$-1.41B$-2.18B$-2.91B
High$-797M$-1.37B$-1.47B$-1.96B
Net Income Avg$372M$768M$1.18B$1.64B
Low$124M$281M$861M$1.20B
High$762M$1.28B$1.45B$2.02B
EPS Avg$4.31$7.58$11.44$15.91
Low$1.20$2.73$8.35$11.61
High$7.39$12.41$14.05$19.55
Analysts (Rev / EPS)10 / 99 / 83 / 64 / 5

Earnings Surprises

Recent Analyst Actions

Jan 14, 2025Piper Sandler
Intra-Cellular downgraded to Neutral from Overweight at Piper Sandler
Target:$132.00
+58.6%from $83.23
Oct 30, 2024Goldman Sachs
Intra-Cellular Therapies (ITCI) PT Raised to $79 at Goldman Sachs
Target:$79.00
-7.6%from $85.47
Sep 5, 2024Piper Sandler
Intra-Cellular upgraded to Overweight from Neutral at Piper Sandler
Target:$92.00
+27.0%from $72.42
Aug 8, 2024RBC Capital
Intra-Cellular Therapies (ITCI) PT Lowered to $106 at RBC Capital
Target:$106.00
+44.0%from $73.63
Aug 7, 2024Goldman Sachs
Intra-Cellular price target lowered to $74 from $77 at Goldman Sachs
Target:$74.00
+0.5%from $73.63
Jul 22, 2024Needham
Intra-Cellular Therapies (ITCI) PT Raised to $100 at Needham
Target:$100.00
+33.6%from $74.86
Jun 25, 2024UBS
UBS Downgrades Intra-Cellular Therapies (ITCI) to Neutral (earlier)
Target:$83.00
+14.6%from $72.42
Jun 20, 2024Mizuho Securities
Intra-Cellular Therapies (ITCI) PT Raised to $100 at Mizuho, 'Top Pick'
Target:$100.00
+31.5%from $76.06
Jun 18, 2024RBC Capital
Intra-Cellular Therapies (ITCI) PT Raised to $103 at RBC Capital
Target:$103.00
+36.5%from $75.48
May 7, 2024RBC Capital
Intra-Cellular Therapies (ITCI) PT Lowered to $96 at RBC Capital
Target:$96.00
+34.8%from $71.21
May 7, 2024Jefferies
Jefferies Positive on Intra-Cellular Therapies (ITCI): 'We like the setup ahead of the second MDD readout in late-Q2'
Target:$105.00
+49.8%from $70.08
Apr 23, 2024Canaccord Genuity
Intra-Cellular Therapies (ITCI) PT Raised to $107 at Canaccord Genuity
Target:$107.00
+43.5%from $74.54
Apr 17, 2024Robert W. Baird
Intra-Cellular Therapies (ITCI) PT Raised to $103 at Baird
Target:$103.00
+29.0%from $79.84
Apr 5, 2024Needham
Needham remains positive on Intra-Cellular ahead of Caplyta readouts
Target:$82.00
+22.0%from $67.21
Jun 13, 2022UBS
Intra-Cellular initiated with a Buy at UBS
Target:$75.00
+41.3%from $53.07
Apr 22, 2022Piper Sandler
Piper Sandler Initiates Coverage On Intra-Cellular Therapies with Neutral Rating, Announces Price Target of $59
Target:$59.00
+5.8%from $55.75
Apr 21, 2022Leerink Partners
SVB Leerink Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $70
Target:$70.00
+16.7%from $59.98
Feb 17, 2022Goldman Sachs
Intra-Cellular Therapies (ITCI) Stock: $64 Price Target From Goldman Sachs
Target:$64.00
+11.3%from $57.49
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.